8DCR image
Entry Detail
PDB ID:
8DCR
EMDB ID:
Title:
Cryo-EM structure of dobutamine-bound beta1-adrenergic receptor in complex with heterotrimeric Gs-protein
Biological Source:
PDB Version:
Deposition Date:
2022-06-17
Release Date:
2022-07-27
Method Details:
Experimental Method:
Resolution:
2.60 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
Chain IDs:C (auth: A)
Chain Length:384
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:A (auth: B)
Chain Length:339
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Chain IDs:D (auth: G)
Chain Length:71
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:Nanobody 35
Chain IDs:B (auth: N)
Chain Length:140
Number of Molecules:1
Biological Source:Lama glama
Polymer Type:polypeptide(L)
Description:Endolysin,Endolysin,Beta-1 adrenergic receptor chimera
Chain IDs:E (auth: R)
Chain Length:508
Number of Molecules:1
Biological Source:Meleagris gallopavo
Ligand Molecules
Primary Citation
Structures of beta 1 -adrenergic receptor in complex with Gs and ligands of different efficacies.
Nat Commun 13 4095 4095 (2022)
PMID: 35835792 DOI: 10.1038/s41467-022-31823-1

Abstact

G-protein-coupled receptors (GPCRs) receive signals from ligands with different efficacies, and transduce to heterotrimeric G-proteins to generate different degrees of physiological responses. Previous studies revealed how ligands with different efficacies activate GPCRs. Here, we investigate how a GPCR activates G-proteins upon binding ligands with different efficacies. We report the cryo-EM structures of β1-adrenergic receptor (β1-AR) in complex with Gs (GαsGβ1Gγ2) and a partial agonist or a very weak partial agonist, and compare them to the β1-AR-Gs structure in complex with a full agonist. Analyses reveal similar overall complex architecture, with local conformational differences. Cellular functional studies with mutations of β1-AR residues show effects on the cellular signaling from β1-AR to the cAMP response initiated by the three different ligands, with residue-specific functional differences. Biochemical investigations uncover that the intermediate state complex comprising β1-AR and nucleotide-free Gs is more stable when binding a full agonist than a partial agonist. Molecular dynamics simulations support the local conformational flexibilities and different stabilities among the three complexes. These data provide insights into the ligand efficacy in the activation of GPCRs and G-proteins.

Legend

Protein

Chemical

Disease

Primary Citation of related structures